Journal of Advanced Medical and Dental Sciences Research

@Society of Scientific Research and Studies NLM ID: 101716117

Journal home page: www.jamdsr.comdoi: 10.21276/jamdsr Indian Citation Index (ICI) Index Copernicus value = 100

(e) ISSN Online: 2321-9599;

(p) ISSN Print: 2348-6805

Case Report

Oral Sub Mucous Fibrosis: Case Report

Kethavath Pawan Kumar Naik¹, Mrudula Raju B², K. Swathi³, K. Lakshmi Poornima⁴, K Sampath⁵, M Srinivasa Raju⁶

¹Post Graduate Student, ²Reader, ⁶Professor and Head of the Department, Department of Oral Medicine and Radiology, St. Joseph Dental College, Duggirala, Eluru, Andhra Pradesh, India; ^{3,4,5}Intern, St. Joseph Dental College, Duggirala, Eluru, Andhra Pradesh, India

ABSTRACT:

Oral submucous fibrosis is an oral precancerous condition characterized by inflammation and progressive fibrosis of sub mucosal tissue resulting in marked rigidity and trismus. OSMF still remains dilemma to the clinicians due to elusive pathogenesis. It may be due to areca nut alkaloids. Progressive in ability to open the mouth due to oral fibrosis and scaring. OSMF is a condition of Oro pharyngeal OSMF of oral cavity in olden days. A precancerous condition is generalized state associated with a significantly increased risk of cancer.

Key-Words: OSMF, Areca Nut, Blanching

Received: 24 June, 2024

Accepted: 28 July, 2024

Corresponding author: Kethavath Pawan Kumar Naik, Post Graduate Student, Department of Oral Medicine and Radiology, St. Joseph Dental College, Duggirala, Eluru, Andhra Pradesh, India

This article may be cited as: Naik KPK, B Mrudula R, Swathi K, Poornima KL, Sampath K, Raju MS. Oral Sub Mucous Fibrosis: Case Report. J Adv Med Dent Scie Res 2024;12(8):69-72.

INTRODUCTION

Oral sub mucous fibrosis (OSMF) is a precancerous condition and it is chronic, resistant disease characterized by juxta epithelial inflammatory reaction and progressive fibrosis of the sub mucosal t issues. In 1966 Pindborg defined OSMF as an insidious chronic disease affecting any part of oral cavity and sometimes the pharynx although occasionally preceded by and/ or associated with vesicle formation it is always associated with juxta epithelial inflammatory reaction followed by a fibroelastic change of lamina propria with epithelial atrophy leading to stiffness of oral mucosa and causing trismus and inability to eat. Other terms used to describe this condition are juxta epithelial fibrosis, Idiopathic scleroderma of the mouth, idiopathic palatal fibrosis, submucous fibrosis of the palate and pillars, sclerosing stomatitis and diffuse osmf. It occurs most commonly seen in young and adult between 25-35 years. Onset of this disease is insidious and is often 2-5 years of duration. The prevalence rate

of OSMF in India is about 0.2%-0.5%. The malignant transformation rate of OSMF was found to be 7.6%. This increased prevalence is due to increased use and popularity of commercially prepared areca nut and tobacco product-gutkha, pan masala, flavoured supari etc. Risk factors: Areca nut chewing, Tobacco use (smoking or smokeless form), genetic predisposition, nutritional deficiency (Vitamin B12 and Iron). Other factors such as hormonal and immunological.

Classification of OSMF (Based on Mouth Opening)

Stage I: Mouth opening greater than 45 mmStage II: Restricted mouth opening 20-44mmStage III: Mouth opening less than 20 mmOMSF is characterised by: • Fibrosis of the oral

mucosa • Blanched and stiffed oral mucosa • Fibrotic bands in the buccal mucosa, tongue and floor of the mouth • Gradual reduction in mouth opening • Difficulty in eating, speaking and swallowing

CASE REPORT



Figure 1: Blanching is Evident on Right and Left Buccal Mucosa

A 20 years male patient came to the department of oral medicine and radiology, St Joseph Dental College Eluru with a chief complaint of missing tooth and pain at the upper front tooth region since 4days. Patient gives h/o pain which is intermittent. Aggravates while taking food and relived by its own. Patient gives h/o pan chewing in the past 2 years. On extra oral examination, on apparent swelling waspresent, on intra oral examination revealed that on inspection blanching is evident on the right and left buccal mucosa. Extending antero-posteriorly from the corner of the mouth to retromolar area superior-inferiorly extending from upper buccal vestibule to lower buccal vestibule. Cheek blowing capacity is reduced. Tongue

movement are normal inter-incisal mouth opening is 35 mm, shrunken uvula is evident, VAS score by patient is 5 and on palpation, all inspector findings are confirmed on palpation. Two vertical bands are palpable extending antero-posteriorly from 2cm from retromolar area superior-inferiorly extending to upper and lower buccal vestibule, rubbery in consistency. No secondary changes are evident. Clinical diagnosis was given as Stage II OSMF involving right and left buccal mucosa.Investigations advised are Toluidine blue staining, HbsAg, Tridot, RBS, CT, BT, CBP.Toluidine blue is retained at both right and left buccal mucosa. Incisional biopsy done under LA and sent for histopathological examination.

Patient Name Mr., AMAN SK OP Reg No OPA410011367 Referred By PrORAL MEDICINE AND Reported On 09-05-2024 11:50 AM Test Name Republic Court Hernoglobin 14:2 RBC count 4,72 RBC 3,72 MCH 30,22 MCH 30,22 MCH 30,22 MCH 30,22 MCH 3,72 RDW 13,8 Platelet Count 8,97 DIFFERENTIAL COUNT Neutrophilis 48 Ecosinophilis 09 Monocytes 03 Basophilis 00	t I <u>MENT OF</u>	Age / Gender Lab Order No Req Date Printed Date Units HAEMATOL OOD PICTUR gm% milliou gm% milliou gm% cumm PERC Laks cumm	: 20Y / Ma : 2024050 : 09-05-21 : 09-05-22 : 09-05-2 : 09-05-	le 19-58 024 11:36 AM 024 11:51 AM Reference Range Male : 12.0 - 18.0 gm % Female: 11.0 - 16.0 gm % 3.5 - 5.5 millournm 40-50% 80-100FL 27-32P9 ERS 32-34gidl 11.6-14.0% 1.5 - 4.5Lakhtournm 4.000 - 11.000/ournm 55 - 70% 25 - 40%
OP Reg No OP Action 10 OP4410011367 Referred By Reported On OP-05-2024 11:50 AM Task Name Result DEPAR COM Hemoglobin Hem	t TMENT OF IPLETE BL	Req Date Printed Date Units HAEMATOL .000 PICTUR gm% milliou PERC FENT PICO GRAN PERC Laks cumm	: 09-05-21 : 09-05-2 OGY E ENTAGE ENTAGE OLITERS VGRAMS CRAMS CENTAGE /Cumm m	024 11:38 AM 024 11:51 AM Reference Range Male : 12.0 - 18.0 gm 5 Female: 11.0 - 16.0 gm 7 3.5 - 5.5 millicumm 40-50% 80-100FL 27-32Pg ERS 32-349dl 11.6-14.0% 1.5-4.5Lakh/cumm 4.000 - 11.00/cumm 55 - 70% 25 - 40%
Referred By Dr. ORAL. MEDICINE: ARL. Reported On :09:05-2024 11:50 AM Test Name Result DE PAR COM DE Count 4.2 RBC count 4.72 PCV 90.9 MCH 30.2 MCHC 13.8 Platelet Count 8.97 Dispected Count 4.0 Usurophils 48 Ecolonghils 00 Biscophils 00 Biscophils 01 Biscophils 01 Biscoling Time 11	I IMENT OF APLETE BL	Req Date Printed Date Units E HAEMATOL OOD PICTUR gm% milliou PERC FENT PICO GRAU PERC Laks cumm % % %	09-05-2 OGY EE mm ENTAGE OLITERS GRAMS WDESI LITE CENTAGE Journm m	024 11:51 AM Reference Range Male : 12.0 - 18.0 gm % Female: 11.0 - 16.0 gm % 3.5 - 55 millournm 40-50% 80-100FL 27-32Pg ERS 32-34gidl 11.6-14.0% 1.5 - 4.5Lakhfournm 4.000 - 11.000/eurnm 55 - 70% 25 - 40%
Reported On : 09-05-2024 11:50 AM Test Name Reput CON Hemoglobin 14.2 RBC count 4.72 RBC count 4.72 RCV 90.9 MCH 30.2 MCHC 30.2 MCHC 30.2 RCW 13.8 Platelet Count 8.97 DIFFERENTIAL COUNT Neutrophils 48 Lymphocytes 48 Lymphocytes 48 BeostingTime 111 BloodingTime 111	t <u>IMENT OF</u> APLETE BL	Printed Date Units E HAEMATOL GOOD PICTUR gm% milliou PERC FENT PICO GRAM PERC Laks cumm % %	OGOUSE COCY EE ENTAGE OLITERS IGRAMS WDESI LITE JOURN MDESI LITE JOURN MDESI LITE	Reference Range Male :12.0 - 18.0 gm % Female: :11.0 - 16.0 gm % 3.5 - 5.5 millioumm 40-50% 80-100FL :27-32Pg 27-32Pg :53.2-34gidl 11.6-14.0% 1.5 - 4.5 Lakh/cumm 4.000 - 11.000/cumm :55 - 70% 25 - 40% :25 - 40%
Test Name Result Test Name DEPAR DEPAR CON Hemoglobin 14.2 RBC count 4.72 PCV 90.9 MCV 30.2 MCH 33.2 MCHC 33.8 Platelet Count 8.97 DIFFERENTIAL COUNT Monocyles Basophils 03 Basophils 13.8	I IMENT OF APLETE BL	HAEMATIC COOD PICTUR gm% milliou PERC FENT PICO GRA PERC Laks cumm % %	OGY E ENTAGE OILITERS JGRAMS W/DESI LITE JCUMM m	Male : 12.0 - 18.0 gm % Female: 11.0 - 16.0 gm % 3.5 - 5.5 millournn 40-50% 80-100FL 27-32Pg ERS 32-34gidl 11.6-14.0% 1.5 - 4.5Lakhtournn 4.000 - 11.000/ournm 55 - 70% 25 - 40%
Test Name DEPAR COM Hemoglobin 14.2 RBC count 4.72 PCV 90.9 MCV 90.2 MCH 33.2 RDW 13.8 Platelet Count 6.97 Total W8C count 6.97 DIFFERENTIAL COUNT 40 Neutrophils 48 Lymphocytes 09 Monocytes 00 Basophils 00	TMENT OF	HEEMALOS GOD PICTUR gm% milliou PERC PICO GRAM PERC Laks cumm % % %	INT ENTAGE OILITERS IGRAMS W/DESI LITE CENTAGE ICUMM m	Male : 12.0 - 18.0 gm 5 Fernale: 11.0 - 16.0 gm 7 3.5 - 5.5 millicumm 40-50% 80-100FL 27-32Pg ERS 32-349/dl 11.6-14.0% 1.5 - 4.5Lakh/cumm 4.000 - 11.00/cumm 55 - 70% 25 - 40%
Hemoglobin 14.2 RBC count 4.72 PCV 90.9 MCV 30.2 MCV 30.2 MCH 33.2 RDW 3.09 Platelet Count 8.97 DIFFERENTAL COUNT 13.8 Platelet Count 8.97 DIFFERENTAL COUNT 40 Neutrophils 48 Ecsinophils 03 Basophils 01 Basophils 11 Bonding Time 11	APLETE BL	COOD PICTUR gm% milliou PICRC FENT PICO GRM PERC Laks cumm % % %	IE ENTAGE OILITERS UGRAMS WIDESI LITE CENTAGE Icumm	Male : 12.0 - 18.0 gm 9 Permale: 11.0 - 16.0 gm 9 3.5 - 5.5 millcurm 40-50% 80-100FL 27-32P 9 ERS 32-34g/dl 11.6-14.0% 1.5 - 4.5Lakh/curnm 4.000 - 11.000/curnm 55 - 70% 25 - 40%
Hemoglobin 14.2 RBC count 4.72 PCV 90.9 MCV 30.2 MCH 33.2 MCHC 33.2 MCHC 30.2 MCHC 30.9 Platelet Count 8.97 DIFFERENTIAL COUNT 40 Nustrophils 48 Eosinophils 03 Basophils 00 Blending Time 11		gm% milliou PERC PENC PICO GRAI PERC Laks cumr % % %	mm ENTAGE OILITERS IGRAMS WIDESI LITE CENTAGE ICUMM	Female: 11.0 - 16.0 gm 7 3.5 - 5.5 milloumm 40-50% 80-100FL 27-32Pg ERS 32-34gidl 11.6-14.0% 1.5 - 4.5Lakh/cumm 4.000 - 11.000/cumm 55 - 70% 25 - 40%
Hemogloom RBC count 4.72 PCV 90.9 MCV 90.9 MCV 30.2 MCH 33.2 MCHC 13.8 RDW 3.09 Flatelet Count 8.97 Total WBC count 8.97 DIFFERENTIAL COUNT 40 Lymphocylas 48 Lymphocylas 48 Bisophils 00 Basophils 01 Bisoding Time 11		milliou PERC FENT PICO GRA PERC Laks cumr % %	mm ENTAGE OILITERS JGRAMS WDESI LITE CENTAGE Journm m	3.6 - 5.5 millioumm 40-50% 80-100FL 27-32Pg ERS 32-349(d) 11.6-14.0% 1.5-4.5Lakh/cumm 4.000-11.000/cumm 55 - 70% 25 - 40%
RBC count 4.72 PCV 42.8 MCV 90.9 MCH 30.2 MCH 30.2 MCH 30.9 Platelet Count 8.97 DIFFERENTIAL COUNT 40 Lymplocytes 09 Ecsinophils 03 Basophils 01 Bloeding Time 11		PERC FENT PICO GRAM PERC Laks cumm % %	ENTAGE OILITERS IGRAMS W/DESI LITE CENTAGE Icumm	40-50% 80-100FL 27-32Pg ERS 32-34g/dl 11.5-14.0% 1.5-4.5Lakh/cumm 4.000 - 11.000/cumm 55 - 70% 25 - 40%
PCV 428 MCV 90.9 MCH 30.2 MCH 33.2 RDW 13.8 Platelet Count 8.97 DIFFERENTIAL COUNT 40 Lympikocylos 48 Eosinophils 03 Monocyles 00 Basophils 11 Bloeding Time 11		FENT PICO GRM PERC Laks cumm % %	O/LITERS /GRAMS w/DESI LITE CENTAGE /cumm m	80-100FL 27-32Pg ERS 32-34g/dl 11.6-14.0% 1.5-4.5Lakh/cumm 4.000-11.000/cumm 55-70% 25-40%
MCV 90.9 MCV 30.2 MCH 33.2 MCHC 33.2 MCHC 33.2 MCHC 33.2 MCHC 33.2 MCHC 30.2 MCHC 30.2		PICO GRAI PERC Laks cumr % %	IGRAMS M/DESILITE CENTAGE /cumm m	27-32P9 ERS 32-34gidl 11.6-14.0% 1.54.5Lakhloumm 4.000 - 11.000/aumm 55 - 70% 25 - 40%
MCH 30.2 MCH 33.2 NCHC 33.2 RDW 3.09 Platelet Count 8.97 DIFFERENTIAL COUNT 40 Neutrophils 48 Lymphocytes 99 Ecsinophils 03 Basophils 01 Basophils 11		GRAM PERC Laks cumr %	WDESILITE CENTAGE <i>icum</i> m m	ERS 32-34gidl 11.6-14.0% 1.54.5Lakh/cumm 4.000 - 11.000/cumm 55 - 70% 25 - 40%
MCHC 3322 RDW 13.8 Platelet Count 3.09 Total WBC count 8.97 DIFFERENTIAL COUNT 40 Neutrophils 48 Lymphocytes 99 Monocytes 03 Basophils 00 Basophils 11 Bloeding Time 11		95 95 95 95	CENTAGE Acumm	11.6-14.0% 1.54.5Lakh/cumm 4.000 - 11.000/cumm 55 - 70% 25 - 40%
RDW 3.09 Platelet Count 3.09 Total WBC count 6.97 DIFFERENTIAL COUNT 40 Lymphocytes 48 Eosinophils 03 Monocytes 03 Basophils 11 Bloeding Time 11		Laks curre % %	icumm m	1.5-4.5Lakh/cumm 4.000 - 11.000/cumm 55 - 70% 25 - 40%
Difference 3.09 Total WBC count 8.97 DiFFERENTIAL COUNT 40 Neutrophilis 48 Lymphocytes 09 Ecsinophilis 03 Basophilis 01 Bloeding Time 11		cum % %	n	4,000 - 11,000/oumm 55 - 70% 25 - 40%
Total WBC count 8.97 DIFFERENTIAL COUNT 40 Neutophia 48 Lymphocytos 99 Bosophilis 03 Basophilis 11 Blooding Time 11		% %		55 - 70% 25 - 40%
DIFFERENTIAL COUNT Neutrophils 40 Lymphocylas 09 Eosinophils 03 Monocylas 00 Basophils 11 Bloeding Time 11		% %		55 - 70% 25 - 40%
Anautophilis 40 Nautophilis 48 Lymphocytes 09 Eosinophilis 03 Monocytes 00 Basophilis 11 Blooding Time 11		%		25-40%
Lympitocytas 09 Ecsinophile 03 Monocytas 00 Basophile 11 Blooding Time 11		9%		
Eosinophile 09 Eosinophile 03 Monocytes 00 Basophile 11 Bloeding Time 11				01 - 08%
Basophils 03 Basophils 00		1%		02-06%
Basophils 00 Bioeding Time 11		56		00-01%
Bloeding Time 11				
Bleeding Time 31		RTCT		The second s
Bleeding Time 11	IN CAREC			1 - 3 minutes
2	MIN 04 SEC			3 - 7 minutes
Clotting Time	MIN 45 SEC			
	DARTMEN	T OF IMMUN	OLOGY	
DE	-Art Intern	HIV		
	ON REACTI	VE		
HIVI	ION REACT	VE		
HIVII	Children			
Statice.		HBs Ag		
and the second se	NEGATIVE			
HBs Ag				v
DE	PARTMEN	T OF BIO-CH	HEMISTR	
		GRBS		en a 160 mold

Figure 2: Haematological Reports



Figure 3: Toluidine Blue Retained On Left Buccal Mucosa



Figure 4: Incisional Biopsy Done At Right Buccal Mucosa

DISCUSSION

OSMF is a chronic insidious disease that is associated with significant functional morbidity and high risk for malignancy transformation. Areca nut chewing, chillies ingestion, immunological patterns and nutritional deficiencies. The high copper content of areca nut increases lysly oxidase activity in return increases fibrosis. It contains alkaloids such as arecoline, acecainide, arecolidina, guacine and guyacoline. Arecoline have cytotoxic effect on cells and promote collagen synthesis. A survey had stated that those who chewed areca nut has possibility of OSMF. Here in the present case, the patienthad the habit of areca nut chewing in the last 1 year. In general, found that areca nut suppresses the appetite and has a psycho-stimulating effect. The content of each packet was betel nuts, catechu, lime, cardamom, menthol, natural artificial flavours, mixed spices and added flavour. It has been reported earlier that patient with sub mucous fibrosis ha oral cancer and associated findings in 5.2%. The present case falls under stage II classification of sub mucous fibrosis. The classification is divided into three stages based on the progression of clinical features of the disease. The clinical signs and symptoms of the disease include

oral ulceration, burning sensation (on taking spicy foods), paleness of the oral mucosa. The most important characteristic feature is the marked vertical fibrous ridge formation within the cheeks and board like stiffness of the buccal mucosa. The fibrosis in the soft tissue leads to trismus, difficulty in eating, and even dysphagia. The diagnosis can be made based on clinical features and symptoms. Out of the above clinical finding's cheek blowing capacity is reduced, inter incisal mouth opening is 35 mm, shrunken uvula is evident and VAS score by patient is 5 were present in this patient. The peak incidence of this condition is in the 35-54-year age group. But in the present case, the age of patient is just 20 years that highlights the need for establishment of a preventive and is a potentially malignant condition.4.5-7.6% is the malignant transformation rate. The possible precancerous nature of OSMF was first described by paymaster. The main problem in treating such a case of OSMF is that the patient does not understand the ill effects and the malignant potential of the areca nut and tobacco. The overall consumption rate of areca nut and tobacco in India is very high leading to increased prevalence of development of such a malignancy condition in children and adults. Hence

the emphasis on generation of awareness regarding the morbidity of the disease is to be addressed among the general population because of the taboos and myths regarding the disease and its cure, efficiently delivering the treatment to the diseased becomes difficult as the cooperation desired becomes from the patient's part is not available. There is a dire need for establishment of a preventive and intervention programme for the malicious habit, the first step being so that young children can be benefited.Based on the histopathological we have concluded that Oral Submucous Fibrosis with moderate epithelial Dysplasia involving right buccal mucosa.

ST.JOSEPH DENTAL	. COLLEGE AND HOSPITAL
DUGG	IRALA, ELURU
HISTOPA	THOLOGY REPORT
PATIENT NAME: SK. AMAR	REFERRED BY: Dr. M.S.RAJU
AGE: 20 973	DEPARTMENT: OMR
SEX: MALE BIOPSY NO: 41/24	SPECIMEN RECEIVED ON: 09/5/24 REPORT DISPATCHED ON: 20/5/24
MACROSCOPIC FEATURES: Received single bit of soft tissue measurin oval in shape, creamish black in color, fir HISTOPATHOLOGIC FEATURES: The given H & E section sh hyperchromatic nuclei, prominent nucle extending till the middle of Stratum spir stellate shaped fibroblasts and few cap adipose tissue and striated muscle. The with moderate epithelial dysplasia.	ng approximately 0.5 x 0.5cm x 0.4 cm in size, round to m in consistency with irregular borders. hows hyperparakeratotic, acanthotic epithelium with coli, acantholysis, increased nuclear cytoplasmic ratio nosum. The underlying connective tissue is dense with illaries. Deeper part of the connective tissue shows se histopathological features are suggestive of OSMF
HISTOPATHOLOGICAL DIAGNO MODERATE EPITHELIAL DYSPLAS	SIS: ORAL SUBMUCOUS FIBROSIS WITH IA. SIGNATURE OF PATHOLOGIST
	Dr. A. JAGADEESH KUMAR

Figure 5: Histopathology Report

CONCLUSION

Oral sub mucous fibrosis is a premalignant condition, progressive disorder with complex mechanism of pathogenesis initiated by inflammation of oral mucosa. Betel quid with areca nut chewing is the main reason for oral sub mucous fibrosis. It has several stages like early OSMF, intermediate OSMF advanced OSMF, burning sensation while taking spicy foods, inability to eat, open mouth, tobacco chewing, alcohol consumption, increase of collagen formation. In this case the patient has the habit of chewing areca nut in the last 2 years which he is not aware of malignancy. We should bring awareness and should conduct camps to bring awareness among youth towards using these harmful substances. The textbooks of these students should include all this awareness lessons. Parents should have an eye on the children about their daily activities. OSMF is a premalignant condition andit may increase its severity if the habit is not stopped. So, quickly bring

awareness among youth and society about all these things to make our nation free from malignancy.

REFERENCES

- 1. Pindborg JJ. Oral submucous fibrosis as a precancerous condition Dent Res 1966; 45:546-53.
- Prabhu SR, Wilson DF, Daftary DK, Johnson NW. Oral Diseases in the Tropics. New York, Toronto: Oxford University Press; 1993. p. 417-22.
- Sabarinath B, Sriram G, Saraswathi TR, Sivapathasundharam B. Immunohistochemical evaluation of mast cells and vascular endothelial proliferation in oral submucous fibrosis. Indian J Dent Res 2011; 22:116-21.
- 4. More CB, Das S, Patel H, Adalja C, Kamatchi V, Venkatesh R. Proposed clinical classification for oral submucous fibrosis. Oral Oncol 2012; 48:200-2.
- TilakaratneWM, Kalinowski MF, SakuT, PetersTJ, Warnakulasuriya S. Oral submucous fibrosis: Review on aetiology and pathogenesis. Oral Oncol 2006; 42:561-8.